DUX4 miRNA Therapy (MyoAAV) (Kate Therapeutics)

N/A

Report date: 2025/01/26 17:33:06
NME

Base Information

Drug NameDUX4 miRNA Therapy (MyoAAV) (Kate Therapeutics)
Drug Alias Namefacioscapulohumeral dystrophy gene therapy (Kate Therapeutics Inc)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionDouble homeobox protein 4 inhibitors
TargetsDouble homeobox protein 4
Therapy Area/IndicationsMuscular Dystrophy, Facioscapulohumeral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Facioscapulohumeral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A